The United States market has shown robust performance, climbing by 2.8% over the past week and rising 25% over the past year, with earnings forecasted to grow annually by 15%. In this thriving environment, identifying high growth tech stocks involves looking for companies that demonstrate strong innovation and adaptability to capitalize on these favorable conditions.
Name | Revenue Growth | Earnings Growth | Growth Rating |
---|---|---|---|
Super Micro Computer | 24.13% | 24.28% | ★★★★★★ |
Ardelyx | 25.47% | 69.63% | ★★★★★★ |
Sarepta Therapeutics | 24.07% | 43.17% | ★★★★★★ |
Alnylam Pharmaceuticals | 22.34% | 70.30% | ★★★★★★ |
Clene | 77.61% | 59.19% | ★★★★★★ |
TG Therapeutics | 34.86% | 56.98% | ★★★★★★ |
Alkami Technology | 21.99% | 102.65% | ★★★★★★ |
Travere Therapeutics | 31.70% | 72.51% | ★★★★★★ |
Seagen | 22.57% | 71.80% | ★★★★★★ |
ImmunoGen | 26.00% | 45.85% | ★★★★★★ |
Click here to see the full list of 238 stocks from our US High Growth Tech and AI Stocks screener.
We'll examine a selection from our screener results.
Simply Wall St Growth Rating: ★★★★☆☆
Overview: Incyte Corporation is a biopharmaceutical company focused on discovering, developing, and commercializing therapeutics for hematology/oncology and inflammation and autoimmunity globally, with a market cap of approximately $13.47 billion.
Operations: Incyte generates revenue primarily from its biotechnology segment, amounting to $4.08 billion. The company focuses on therapeutics for hematology/oncology and inflammation and autoimmunity across the U.S. and international markets.
Incyte's recent advancements underscore its commitment to innovation, particularly with the promising results from the Phase 3 POD1UM-304 trial of Zynyz® in treating non-small cell lung cancer, showing a notable improvement in median overall survival rates. This progress is crucial as it not only enhances Incyte’s portfolio but also solidifies its position in oncology therapeutics. Financially, Incyte has adjusted its revenue guidance upwards to $2.74 billion to $2.77 billion for 2024, reflecting confidence in its core products like Jakafi amidst a competitive market landscape. Despite some setbacks in other trials, such as the pausing of enrollment for INCB000262 due to preclinical findings, Incyte's strategic focus on high-stakes oncology treatments and robust R&D investment—which remains a significant part of their expenditure—positions it uniquely within the biotech sector for potential growth and patient impact.
Understand Incyte's track record by examining our Past report.
Simply Wall St Growth Rating: ★★★★★★
Overview: Super Micro Computer, Inc. develops and manufactures high performance server and storage solutions using modular and open architecture across various regions globally, with a market cap of $20.10 billion.
Operations: The company focuses on developing and providing high-performance server solutions, generating approximately $14.94 billion in revenue. Its operations span the United States, Europe, Asia, and other international markets.
Super Micro Computer has faced significant challenges, including being removed from the NASDAQ-100 Index and receiving a non-compliance notification from Nasdaq due to delays in its financial reporting. These issues are critical as they reflect on the company’s operational and regulatory challenges. Despite these setbacks, Super Micro remains at the forefront of technological innovation in data centers, particularly with its advancements in liquid-cooled systems and partnerships with NVIDIA for next-gen AI infrastructures. This focus on high-performance computing solutions positions them uniquely within tech sectors reliant on advanced computing capabilities.
Examine Super Micro Computer's past performance report to understand how it has performed in the past.
Simply Wall St Growth Rating: ★★★★★☆
Overview: ServiceNow, Inc. offers an intelligent workflow automation platform for digital businesses across various regions globally and has a market cap of $228.10 billion.
Operations: The company generates revenue primarily from its Internet Software & Services segment, amounting to $10.46 billion.
ServiceNow, a key figure in the digital transformation landscape, has demonstrated robust growth with a notable 16.9% annual revenue increase and an impressive 22.1% forecast in earnings growth per year. The company's commitment to innovation is underscored by its strategic investments in R&D, which have consistently aligned with or exceeded industry standards, ensuring its competitive edge in the fast-evolving tech sector. Recent strategic alliances, such as those with Amazon Web Services and Tech Mahindra, not only expand ServiceNow's operational capabilities but also enhance its product offerings with cutting-edge AI integrations that are set to redefine enterprise service management across various industries. These collaborations are pivotal as they leverage ServiceNow's platform strengths to drive significant efficiencies and customer value creation through advanced technological deployments.
Explore historical data to track ServiceNow's performance over time in our Past section.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include NasdaqGS:INCY NasdaqGS:SMCI and NYSE:NOW.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。